{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-005322","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.840745+00:00","generated_at":"2026-05-17T23:08:24.814085+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia","bullets":["BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.","VitaGuard is tumour-naïve ctDNA test with 0.02% VAF sensitivity, 95% cfDNA recovery; cost <$300 vs >$3,000 legacy assays.","Southeast Asia cancer incidence projected at 2.4M new cases annually by 2030, creating multi-billion-dollar recurring market.","Cross-shareholdings and license fee align both companies; rollout begins in Singapore and Malaysia.","Partnership includes joint development of companion diagnostics and AI-powered Cancer Interception System."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-005322","json":"https://secwatch.observer/filing/0001477932-25-005322.json","markdown":"https://secwatch.observer/filing/0001477932-25-005322.md","text":"https://secwatch.observer/filing/0001477932-25-005322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225005322/0001477932-25-005322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225005322/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:08:24.814085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}